Computational Screening of Heterocyclic L-Type Calcium Channel Blockers for Potential Anti-Parkinson’s Activity
Treating cardiovascular disorders like hypertension, arrhythmias, angina pectoris, and congestive heart failure involves using calcium channel blockers that bind allosterically to Cave L-type channels in myocytes in cardiac muscle. The heterocyclic compounds like 1, 4 dihydropyridines, phenyl a...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Krupanidhi College of Pharmacy
2025-03-01
|
| Series: | Journal of Pharmaceutical Research |
| Online Access: | https://jopcr.com/articles/computational-screening-of-heterocyclic-l-type-calcium-channel-blockers-for-potential-anti-parkinsons-activity |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849230143242895360 |
|---|---|
| author | Thomas Kurian Rani Sebastian |
| author_facet | Thomas Kurian Rani Sebastian |
| author_sort | Thomas Kurian |
| collection | DOAJ |
| description |
Treating cardiovascular disorders like hypertension, arrhythmias, angina pectoris, and congestive heart failure involves using calcium channel blockers that bind allosterically to Cave L-type channels in myocytes in cardiac muscle. The heterocyclic compounds like 1, 4 dihydropyridines, phenyl alkyl amines, and benzodiazepines are calcium antagonists for cardiac diseases. The receptor protein CavAb in complex with Br- Verapamil was selected as a target for studying the interaction and prediction of calcium channel blocking activity of five heterocyclic compounds based on chemical structural features. using two popular software’s, Auto Dock and PyRx. The results predicted the activity of "2-(3, 4-methoxyphenyl)-5-(2, 2-phenylethylamine)-2-propan-2-ylpentanenitrile" and was chosen as the best score -6.9 – (strong) by auto dock and -9.8 by PyRX compared to the standard verapamil. Verapamil: - PyRX: -6.5, - Auto Dock: -5.22, Higher anticipated activity compounds (strong): 1. [(3R, 4S)-1-[2-ethyl (dimethylamine)]-4 (four-methoxyphenyl)5-dihydro-3H-1-benzazepin-3-yl, -7-methylsulfanyl-2-oxo-4] Acetate: - PyRX: -7.9, 2. 2-(3,4-ethoxyphenyl) - Auto Dock: -5.37(2) Phenyl ethylamine -5-2-propane-2-ylpentanenitrile:- PyRX: -9.8 molecules with weak estimated activity - Auto Dock: -6.251. 5-dicarboxylate, 4-dihydropyridine-3, 6-dimethyl-4-(3-nitrophenyl)-1, diethyl 2, PyRX: -7.2, 2. 4'- hydroxy-3'-methoxy acetophenone, Auto Dock: -3.81 PyRX: -5.6, Auto Dock: -4.31, 3. 1,4-dihydropyridine-3,5-dicarboxylate is diethyl 2,6-dimethyl-4-(4-nitrophenyl):PyRX: -6.8, Auto Dock: -4.52.Calcium channel blockers antiparkinson's effect is under recent global investigations. The ADME parameters studied for the compound were Inhibition of CYP1A2, BBB permeability, distribution, total clearance, oral rat acute toxicity (LD50), and toxicity with Swiss-ADME software. Lead optimization by identifying a molecule's salient characteristics will contribute to toxicity and building safer analogs.
Keywords: Docking, Parkinson's, Heterocyclic, Auto dock Vina, PyRX |
| format | Article |
| id | doaj-art-2d313a40b1ea49a3b8af7b930446960b |
| institution | Kabale University |
| issn | 0973-7200 2454-8405 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Krupanidhi College of Pharmacy |
| record_format | Article |
| series | Journal of Pharmaceutical Research |
| spelling | doaj-art-2d313a40b1ea49a3b8af7b930446960b2025-08-21T09:34:08ZengKrupanidhi College of PharmacyJournal of Pharmaceutical Research0973-72002454-84052025-03-01241454810.18579/jopcr/v24.i1.23Computational Screening of Heterocyclic L-Type Calcium Channel Blockers for Potential Anti-Parkinson’s ActivityThomas KurianRani Sebastian Treating cardiovascular disorders like hypertension, arrhythmias, angina pectoris, and congestive heart failure involves using calcium channel blockers that bind allosterically to Cave L-type channels in myocytes in cardiac muscle. The heterocyclic compounds like 1, 4 dihydropyridines, phenyl alkyl amines, and benzodiazepines are calcium antagonists for cardiac diseases. The receptor protein CavAb in complex with Br- Verapamil was selected as a target for studying the interaction and prediction of calcium channel blocking activity of five heterocyclic compounds based on chemical structural features. using two popular software’s, Auto Dock and PyRx. The results predicted the activity of "2-(3, 4-methoxyphenyl)-5-(2, 2-phenylethylamine)-2-propan-2-ylpentanenitrile" and was chosen as the best score -6.9 – (strong) by auto dock and -9.8 by PyRX compared to the standard verapamil. Verapamil: - PyRX: -6.5, - Auto Dock: -5.22, Higher anticipated activity compounds (strong): 1. [(3R, 4S)-1-[2-ethyl (dimethylamine)]-4 (four-methoxyphenyl)5-dihydro-3H-1-benzazepin-3-yl, -7-methylsulfanyl-2-oxo-4] Acetate: - PyRX: -7.9, 2. 2-(3,4-ethoxyphenyl) - Auto Dock: -5.37(2) Phenyl ethylamine -5-2-propane-2-ylpentanenitrile:- PyRX: -9.8 molecules with weak estimated activity - Auto Dock: -6.251. 5-dicarboxylate, 4-dihydropyridine-3, 6-dimethyl-4-(3-nitrophenyl)-1, diethyl 2, PyRX: -7.2, 2. 4'- hydroxy-3'-methoxy acetophenone, Auto Dock: -3.81 PyRX: -5.6, Auto Dock: -4.31, 3. 1,4-dihydropyridine-3,5-dicarboxylate is diethyl 2,6-dimethyl-4-(4-nitrophenyl):PyRX: -6.8, Auto Dock: -4.52.Calcium channel blockers antiparkinson's effect is under recent global investigations. The ADME parameters studied for the compound were Inhibition of CYP1A2, BBB permeability, distribution, total clearance, oral rat acute toxicity (LD50), and toxicity with Swiss-ADME software. Lead optimization by identifying a molecule's salient characteristics will contribute to toxicity and building safer analogs. Keywords: Docking, Parkinson's, Heterocyclic, Auto dock Vina, PyRXhttps://jopcr.com/articles/computational-screening-of-heterocyclic-l-type-calcium-channel-blockers-for-potential-anti-parkinsons-activity |
| spellingShingle | Thomas Kurian Rani Sebastian Computational Screening of Heterocyclic L-Type Calcium Channel Blockers for Potential Anti-Parkinson’s Activity Journal of Pharmaceutical Research |
| title | Computational Screening of Heterocyclic L-Type Calcium Channel Blockers for Potential Anti-Parkinson’s Activity |
| title_full | Computational Screening of Heterocyclic L-Type Calcium Channel Blockers for Potential Anti-Parkinson’s Activity |
| title_fullStr | Computational Screening of Heterocyclic L-Type Calcium Channel Blockers for Potential Anti-Parkinson’s Activity |
| title_full_unstemmed | Computational Screening of Heterocyclic L-Type Calcium Channel Blockers for Potential Anti-Parkinson’s Activity |
| title_short | Computational Screening of Heterocyclic L-Type Calcium Channel Blockers for Potential Anti-Parkinson’s Activity |
| title_sort | computational screening of heterocyclic l type calcium channel blockers for potential anti parkinson s activity |
| url | https://jopcr.com/articles/computational-screening-of-heterocyclic-l-type-calcium-channel-blockers-for-potential-anti-parkinsons-activity |
| work_keys_str_mv | AT thomaskurian computationalscreeningofheterocyclicltypecalciumchannelblockersforpotentialantiparkinsonsactivity AT ranisebastian computationalscreeningofheterocyclicltypecalciumchannelblockersforpotentialantiparkinsonsactivity |